Treatment Interventions for the Management of Intestinal Permeability: A Cross-Sectional Survey of Complementary and Integrative Medicine Practitioners
Restricted accessResearch articleFirst published online June, 2019
Treatment Interventions for the Management of Intestinal Permeability: A Cross-Sectional Survey of Complementary and Integrative Medicine Practitioners
This study aims to explore the treatment interventions complementary and integrative medicine (CIM) practitioners use in the management of an emerging health condition, increased intestinal permeability (IP), and the association these methods have on the observed time to resolve this condition.
Design and setting:
A cross-sectional survey of Australian naturopaths, nutritionists, and Western herbal medicine practitioners was undertaken (n = 227) through the Practitioner Research and Collaboration Initiative (PRACI) network.
Outcome measures:
Frequencies and percentages of the treatment methods, including chi-square analysis to examine the associations between treatment methods and observed time to resolve IP.
Results:
Thirty-six CIM practitioners responded to the survey (response rate 15.9%). CIM practitioners were found to use a multimodal approach in the management of IP with 92.6% of respondents using three or more categories of treatment interventions (nutritional, herbal, dietary, and lifestyle) with a mean total of 43.0 ± 24.89 single treatment interventions frequently prescribed. The main treatments prescribed in the management of IP were zinc (85.2%), probiotics: multistrain (77.8%), vitamin D (75.0%), glutamine (73.1%), Curcuma longa (73.1%), and Saccharomyces boulardii (70.4%). CIM practitioners also advocate patients with IP to reduce alcohol (96.3%), gluten (85.2%), and dairy (75.0%) consumption. Evaluation of antibiotics (75.0%) and nonsteroidal anti-inflammatory drugs (73.1%) prescriptions were frequently advised by CIM practitioners. A longer observed time to resolve IP was seen in CIM practitioners who did not reduce intense exercise in the management of IP (p = 0.02).
Conclusions:
This study represents the first survey of the treatments prescribed by CIM practitioners for IP and suggests that CIM practitioners use numerous integrative treatment methods for the management of IP. The treatment interventions frequently prescribed by CIM practitioners align with preclinical research, suggesting that CIM practitioners prescribe in accordance with the published literature. The findings of this study contribute to the implementation of clinical research in the management of IP, which considers multiple concurrent treatments.
Get full access to this article
View all access options for this article.
References
1.
AliA, KatzDL. Disease prevention and health promotion: How integrative medicine fits. Am J Prev Med, 2015; 49(Suppl 3):S230–S240.
2.
LanghorstJ, WulfertH, LaucheR, et al.Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis, 2015; 9:86–106.
3.
BreckenridgeJP, GianfrancescoC, de ZoysaN, et al.Mobilising knowledge between practitioners and researchers to iteratively refine a complex intervention (DAFNEplus) pre-trial: Protocol for a structured, collaborative working group process. Pilot Feasibility Stud, 2018; 4:120.
4.
ThorpeKE, ZwarensteinM, OxmanAD, et al.A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. J Clin Epidemiol, 2009; 62:464–475.
5.
CotterillS, KnowlesS, MartindaleAM, et al.Getting messier with TIDieR: Embracing context and complexity in intervention reporting. BMC Med Res Methodol, 2018; 18:12.
6.
LeechB, SchlossJ, SteelA. Health services research as a framework for expanding a whole systems research agenda in complementary and integrative medicine: The example of intestinal permeability. Eur J Integr Med, 2018; 17:22–25.
7.
LeechB, SchlossJ, SteelA. Investigation into complementary and integrative medicine practitioners' clinical experience of intestinal permeability: A cross-sectional survey. Complement Ther Clin Pract, 2018; 31:200–209.
8.
FasanoA. Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications. Clin Gastroenterol Hepatol, 2012; 10:1096–1100.
9.
DastychM, DastychMJr., NovotnaH, et al.Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. Dig Dis Sci, 2008; 53:2789–2792.
10.
BuhnerS, BuningC, GenschelJ, et al.Genetic basis for increased intestinal permeability in families with Crohn's disease: Role of CARD15 3020insC mutation?. Gut, 2006; 55:342–347.
11.
ElaminE, MascleeA, TroostF, et al.Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: A combined in vivo and in vitro approach. PloS One, 2014; 9:e107421.
12.
SuzukiT. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci, 2013; 70:631–659.
13.
BischoffSC, BarbaraG, BuurmanW, et al.Intestinal permeability—A new target for disease prevention and therapy. BMC Gastroenterol, 2014; 14:189.
CollinsFL, Rios-ArceND, AtkinsonS, et al.Temporal and regional intestinal changes in permeability, tight junction, and cytokine gene expression following ovariectomy-induced estrogen deficiency. Physiol Rep, 2017; 5:e13263.
16.
FukuiH. Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation?. Inflamm Intest Dis, 2016; 1:135–145.
17.
HollonJ, PuppaEL, GreenwaldB, et al.Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity. Nutrients, 2015; 7:1565–1576.
18.
SamselA, SeneffS. Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance. Interdiscip Toxicol, 2013; 6:159–184.
19.
De SantisS, CavalcantiE, MastronardiM, et al.Nutritional keys for intestinal barrier modulation. Front Immunol, 2015; 6:612.
20.
LamprechtM, BognerS, SchippingerG, et al.Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr, 2012; 9:45.
21.
KerckhoffsAP, AkkermansLM, de SmetMB, et al.Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs. Dig Dis Sci, 2010; 55:716–723.
22.
TulstrupMV, ChristensenEG, CarvalhoV, et al.Antibiotic treatment affects intestinal permeability and gut microbial composition in wistar rats dependent on antibiotic class. PloS One, 2015; 10:e0144854.
23.
LefflerDA, KellyCP, GreenPH, et al.Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: A randomized controlled trial. Gastroenterology, 2015; 148:1311–1319.E1316.
24.
Garcia VilelaE, De Lourdes De Abreu FerrariM, Oswaldo Da Gama TorresH, et al.Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol, 2008; 43:842–848.
25.
DavisonG, MarchbankT, MarchDS, et al.Zinc carnosine works with bovine colostrum in truncating heavy exercise-induced increase in gut permeability in healthy volunteers. Am J Clin Nutr, 2016; 104:526–536.
26.
RafteryT, MartineauAR, GreillerCL, et al.Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study. United European Gastroenterol J, 2015; 3:294–302.
27.
BeguinP, ErrachidA, LarondelleY, et al.Effect of polyunsaturated fatty acids on tight junctions in a model of the human intestinal epithelium under normal and inflammatory conditions. Food Funct, 2013; 4:923–931.
28.
SteelA, AdamsJ, SibbrittD. Developing a multi-modality complementary medicine practice-based research network: The PRACI project. Adv Integr Med, 2014; 1:113–118.
SarrisJ, WardleJ. Clinical Naturopathy: An Evidence-Based Guide to Practice, 2nd ed. Sydney: Elsevier Australia, 2014.
31.
ShintoL, CalabreseC, MorrisC, et al.Complementary and alternative medicine in multiple sclerosis: Survey of licensed naturopaths. J Altern Complement Med, 2004; 10:891–897.
32.
LundyJ, CraigBM. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: Analysis of claims data from the medicare current beneficiary survey. Clin Ther, 2006; 28:140–145.
33.
KelleyJM, Kraft-ToddG, SchapiraL, et al.The influence of the patient-clinician relationship on healthcare outcomes: A systematic review and meta-analysis of randomized controlled trials. PloS One, 2014; 9:e94207.
34.
RacicM, KusmukS, MasicS, et al.Impact of the physician-patient relationship on the treatment outcomes of arterial hypertension. Opsta Med, 2017; 23:1–8.
35.
KwakDS, JunDW, SeoJG, et al.Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur J Gastroenterol Hepatol, 2014; 26:1353–1359.
36.
FukuiH, KitanoH, OkamotoY, et al.Interaction of Kupffer cells to splenic macrophages and hepatocytes in endotoxin clearance: Effect of alcohol. J Gastroenterol Hepatol, 1995; 10(Suppl 1):S31–S34.
37.
ShethP, SethA, AtkinsonKJ, et al.Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J, 2007; 402:291–300.
38.
KeshavarzianA, FarhadiA, ForsythCB, et al.Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol, 2009; 50:538–547.
39.
ForsythCB, VoigtRM, KeshavarzianA. Intestinal CYP2E1: A mediator of alcohol-induced gut leakiness. Redox Biol, 2014; 3:40–46.
40.
WangY, TongJ, ChangB, et al.Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins. Mol Med Rep, 2014; 9:2352–2356.
41.
BjarnasonI, PetersTJ, WiseRJ. The leaky gut of alcoholism: Possible route of entry for toxic compounds. Lancet, 1984; 1:179–182.
42.
SethA, BasuroyS, ShethP, et al.L-glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Am J Physiol Gastrointest Liver Physiol, 2004; 287:G510–G517.
43.
ZhongW, McClainCJ, CaveM, et al.The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol, 2010; 298:G625–G633.
44.
SchlossJ, McIntyreE, RickwoodC, et al.Identification of the conditions that complementary medicine practitioners recommend gluten free diets for in Australia. Adv Integr Med, 2018. https://doi.org/10.1016/j.aimed.2018.06.003.
45.
CostaRJS, SnipeRMJ, KiticCM, et al.Systematic review: Exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. Aliment Pharmacol Ther, 2017; 46:246–265.
46.
Van HoutenJM, WessellsRJ, LujanHL, et al.My gut feeling says rest: Increased intestinal permeability contributes to chronic diseases in high-intensity exercisers. Med Hypotheses, 2015; 85:882–886.
47.
PughJN, SageS, HutsonM, et al.Glutamine supplementation reduces markers of intestinal permeability during running in the heat in a dose-dependent manner. Eur J Appl Physiol, 2017; 117:2569–2577.
48.
de OliveiraEP, BuriniRC, JeukendrupA. Gastrointestinal complaints during exercise: Prevalence, etiology, and nutritional recommendations. Sports Med, 2014; 44(Suppl 1):S79–S85.
49.
KongJ, ZhangZ, MuschMW, et al.Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol, 2008; 294:G208–G216.
50.
GhoshSS, BieJ, WangJ, et al.Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice—Role of intestinal permeability and macrophage activation. PloS One, 2014; 9:e108577.
51.
OrlandoA, LinsalataM, NotarnicolaM, et al.Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: The role of cellular polyamines. BMC Microbiol, 2014; 14:19.
52.
BertrandJ, GhouzaliI, GuerinC, et al.Glutamine restores tight junction protein claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable Bowel syndrome. JPEN J Parenter Enteral Nutr, 2016; 40:1170–1176.
53.
ShaoY, WolfPG, GuoS, et al.Zinc enhances intestinal epithelial barrier function through the PI3K/AKT/mTOR signaling pathway in Caco-2 cells. J Nutr Biochem, 2017; 43:18–26.
54.
TercioloC, DobricA, OuaissiM, et al.Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recycling. J Crohns Colitis, 2017; 11:999–1010.
55.
ThomasS, MetzkeD, SchmitzJ, et al.Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol, 2011; 301:G1083–G1092.
56.
JustinoPF, MeloLF, NogueiraAF, et al.Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. Br J Nutr, 2014; 111:1611–1621.
57.
DuJ, ChenY, ShiY, et al.1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. Inflamm Bowel Dis, 2015; 21:2495–2506.
58.
KrishnanM, PenroseHM, ShahNN, et al.VSL#3 probiotic stimulates T-cell protein tyrosine phosphatase-mediated recovery of IFN-gamma-induced intestinal epithelial barrier defects. Inflamm Bowel Dis, 2016; 22:2811–2823.
59.
ShingCM, PeakeJM, LimCL, et al.Effects of probiotics supplementation on gastrointestinal permeability, inflammation and exercise performance in the heat. Eur J Appl Physiol, 2014; 114:93–103.
60.
LeberB, TripoltNJ, BlattlD, et al.The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study. Eur J Clin Nutr, 2012; 66:1110–1115.
61.
FrancavillaR, MinielloV, MagistaAM, et al.A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics, 2010; 126:e1445–e1452.
62.
FinamoreA, MassimiM, Conti DevirgiliisL, et al.Zinc deficiency induces membrane barrier damage and increases neutrophil transmigration in Caco-2 cells. J Nutr, 2008; 138:1664–1670.
63.
WangTT, NestelFP, BourdeauV, et al.Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol, 2004; 173:2909–2912.
64.
WangB, WuZ, JiY, et al.L-glutamine enhances tight junction integrity by activating CaMK kinase 2-AMP-activated protein kinase signaling in intestinal porcine epithelial cells. J Nutr, 2016; 146:501–508.
65.
XueH, SlavovD, WischmeyerPE. Glutamine-mediated dual regulation of heat shock transcription factor-1 activation and expression. J Biol Chem, 2012; 287:40400–40413.
66.
ShuXL, YuTT, KangK, et al.Effects of glutamine on markers of intestinal inflammatory response and mucosal permeability in abdominal surgery patients: A meta-analysis. Exp Ther Med, 2016; 12:3499–3506.
67.
BenjaminJ, MakhariaG, AhujaV, et al.Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn's disease: A randomized controlled trial. Dig Dis Sci, 2012; 57:1000–1012.
68.
ZuhlM, DokladnyK, MermierC, et al.The effects of acute oral glutamine supplementation on exercise-induced gastrointestinal permeability and heat shock protein expression in peripheral blood mononuclear cells. Cell Stress Chaperones, 2015; 20:85–93.
69.
ZhangLJ, WuCF, MengXL, et al.Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci Lett, 2008; 447:48–53.
70.
ThamCL, LiewCY, LamKW, et al.A synthetic curcuminoid derivative inhibits nitric oxide and proinflammatory cytokine synthesis. Eur J Pharmacol, 2010; 628:247–254.
71.
SougioultzisS, SimeonidisS, BhaskarKR, et al.Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun, 2006; 343:69–76.
MutluEA, GillevetPM, RangwalaH, et al.Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol, 2012; 302:G966–G978.
74.
DragoS, El AsmarR, Di PierroM, et al.Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol, 2006; 41:408–419.
75.
LammersKM, LuR, BrownleyJ, et al.Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology, 2008; 135:194–204.e193.
76.
MazzarellaG, SalvatiVM, IaquintoG, et al.Reintroduction of gluten following flour transamidation in adult celiac patients: A randomized, controlled clinical study. Clin Dev Immunol, 2012; 2012:329150.
77.
JianqinS, LeimingX, LuX, et al.Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk. Nutr J, 2016; 15:35.
78.
DupontC, BarauE, MolkhouP, et al.Food-induced alterations of intestinal permeability in children with cow's milk-sensitive enteropathy and atopic dermatitis. J Pediatr Gastroenterol Nutr, 1989; 8:459–465.
79.
NevadoR, ForcenR, LayuntaE, et al.Neomycin and bacitracin reduce the intestinal permeability in mice and increase the expression of some tight-junction proteins. Rev Esp Enferm Dig, 2015; 107:672–676.
80.
KoidoS, OhkusaT, KajiuraT, et al.Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy. PLoS One, 2014; 9:e86702.
81.
WlodarskaM, WillingB, KeeneyKM, et al.Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect Immun, 2011; 79:1536–1545.
82.
ConaghanPG. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int, 2012; 32:1491–1502.
83.
SomasundaramS, RafiS, HayllarJ, et al.Mitochondrial damage: A possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut, 1997; 41:344–353.
84.
FukuiA, NaitoY, HandaO, et al.Acetyl salicylic acid induces damage to intestinal epithelial cells by oxidation-related modifications of ZO-1. Am J Physiol Gastrointest Liver Physiol, 2012; 303:G927–G936.
85.
SequeiraIR, LentleRG, KrugerMC, et al.Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability. PLoS One, 2014; 9:e99256.
86.
SequeiraIR, LentleRG, KrugerMC, et al.Assessment of the effect of intestinal permeability probes (lactulose and mannitol) and other liquids on digesta residence times in various segments of the gut determined by wireless motility capsule: A randomised controlled trial. PLoS One, 2015; 10:e0143690.
87.
SegarJ. Complementary and alternative medicine: Exploring the gap between evidence and usage. Health (London), 2012; 16:366–381.
88.
SteelA, AdamsJ. The application and value of information sources in clinical practice: An examination of the perspective of naturopaths. Health Info Libr J, 2011; 28:110–118.
89.
VanGeestJB, JohnsonTP, WelchVL. Methodologies for improving response rates in surveys of physicians: A systematic review. Eval Health Prof, 2007; 30:303–321.
